

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LAMPROPOULOS FRED P</u> (Last) (First) (Middle) 1600 WEST MERIT PARKWAY (Street) SOUTH UT 84095 JORDAN (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MERIT MEDICAL SYSTEMS INC [MMSI]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) PRESIDENT AND CEO
	3. Date of Earliest Transaction (Month/Day/Year) 02/28/2023	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, No Par Value	02/28/2023		A		27,159 ⁽¹⁾	A	\$0	1,025,582	D	
Common Stock, No Par Value	02/28/2023		F		12,030 ⁽²⁾	D	\$70.58	1,013,552	D	
Common Stock, No Par Value	03/01/2023		S		1,483	D	\$70.1743 ⁽³⁾	1,012,069	D	
Common Stock, No Par Value	03/02/2023		S		19,176	D	\$69.859 ⁽⁴⁾	992,893	D	
Common Stock, No Par Value								96,841	I	By 401(k) Plan ⁽⁵⁾
Common Stock, No Par Value								90	I	By spouse as custodian for child ⁽⁶⁾
Common Stock, No Par Value								6,888	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-qualified stock options (right to buy)	\$70.58	02/28/2023		A		54,302		02/28/2024 ⁽⁷⁾	02/28/2030	Common Stock	54,302	\$0	54,302	D	
Non-qualified stock options (right to buy)	\$28.2							04/14/2018 ⁽⁸⁾	04/14/2024	Common Stock	200,000		200,000	D	
Non-qualified stock options (right to buy)	\$28.2							04/14/2018 ⁽⁹⁾	04/14/2024	Common Stock	6,000		6,000	I	By spouse ⁽¹⁰⁾
Non-qualified stock options (right to buy)	\$44.8							03/02/2019 ⁽¹¹⁾	03/02/2025	Common Stock	38,002		38,002	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)				5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Non-qualified stock options (right to buy)	\$44.8								03/02/2019 ⁽¹²⁾	03/02/2025	Common Stock	4,000		4,000	I	By spouse ⁽¹⁰⁾	
Non-qualified stock options (right to buy)	\$55.73								03/01/2020 ⁽¹³⁾	03/01/2026	Common Stock	159,151		159,151	D		
Non-qualified stock options (right to buy)	\$55.73								03/01/2020 ⁽¹⁴⁾	03/01/2026	Common Stock	2,000		2,000	I	By spouse ⁽¹⁰⁾	
Non-qualified stock options (right to buy)	\$37.71								02/26/2021 ⁽¹⁵⁾	02/26/2027	Common Stock	100,334		100,334	D		
Non-qualified stock options (right to buy)	\$56.25								03/19/2022 ⁽¹⁶⁾	03/19/2028	Common Stock	58,083		58,083	D		

Explanation of Responses:

- These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee and Board of Directors that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02.26.2020 and 03.19.2021.
- These shares were not sold in an open-market transaction.
- The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$70.00 to \$70.44 inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$69.6 to \$70.1 inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- Represents plan holdings as of 01/31/2023.
- Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.
- Becomes exercisable in equal annual installments of 25% commencing 02/28/2024.
- Becomes exercisable in equal annual installments of 20% commencing 4/14/2018.
- Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 4/14/2018. Options not vested as of 6/22/2020 have been forfeited.
- Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.
- Becomes exercisable in equal annual installments of 20% commencing 3/2/2019.
- Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/2/2019. Options not vested as of 6/22/2020 have been forfeited.
- Becomes exercisable in equal annual installments of 20% commencing 3/1/2020.
- Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/1/2020. Options not vested as of 6/22/2020 have been forfeited.
- Becomes exercisable in equal annual installments of 25% commencing 2/26/2021.
- Becomes exercisable in equal annual installments of 25% commencing 3/19/2022.

/s/ Brian G. Lloyd, Attorney-in-Fact 03/02/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.